EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Primary breast diffuse large B‐cell lymphoma in the rituximab era: A retrospective study of the Chinese Southwest Oncology Group

Huawei Weng iD, Prem Raj Shrestha, Huangming Hong iD, Zegeng Chen iD, Le Yu, Yuyi Yao, Zhihui Zhang, Liqun Zou, Bo Zhu, Hui Zhou, Xianling Liu, Yao Liu und 3 weitere

Cancer Medicine · 2023

DOI: 10.1002/cam4.6686 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2023. Verfasst von Huawei Weng und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Cente…. Hauptthemen laut MEDLINE: Breast Neoplasms, Lymphoma, Large B-Cell, Diffuse, Central Nervous System Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Outstanding Young Scientific and Technological Talents Fund of Sichuan Province, Regional Innovation Cooperation Project of Science and Technology Department of Sichuan Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Primary breast diffuse large B‐cell lymphoma (PB‐DLBCL) is a rare subtype of extranodal DLBCL, and the standard treatment remains controversial. In this study, we aimed to define the optimal treatment management in the rituximab era.

Methods

A total of 5089 newly diagnosed DLBCL patients treated with rituximab‐containing immunochemotherapy between 2008 and 2019 from the Chinese Southwest Oncology Group‐affiliated institutes were identified, of whom 135 diagnosed with PB‐DLBCL were eligible for this analysis.

Results

PB‐DLBCL accounted for 2.7% of all DLBCLs. With a median follow‐up of 4.2 years, the 5‐year overall survival and progression‐free survival rates were 84.8% and 71.6%, respectively. Breast and central nervous system (CNS) relapses were the main cause of treatment failure. We observed that consolidative breast radiotherapy (RT) significantly decreased breast relapse risk (5‐year risk, 2.9% vs. 20.1%, p = 0.007). The CNS relapse risk was lower for patients who received high‐dose methotrexate (HD‐MTX) than for patients who did not (5‐year risk, 0% vs. 15.2%, p = 0.015). We further screened the genetic mutation profile of 20 patients from two institutes, and found that MYD88 (25%) and CD79B mutations (25%) frequently occur in PB‐DLBCL. In addition, four patients with MYD88 and/or CD79B mutations experienced CNS relapse, while three patients with MYD88 and/or CD79B mutations who received HD‐MTX did not experience CNS relapse.

Conclusion

Collectively, our results indicate combined modality therapy including rituximab‐containing immunochemotherapy and consolidative breast RT is a promising approach for PB‐DLBCL, while HD‐MTX is useful for preventing CNS relapse.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsLymphoma, Large B-Cell, DiffuseCentral Nervous System NeoplasmsHumansFemaleRituximabRetrospective StudiesMyeloid Differentiation Factor 88Neoplasm Recurrence, LocalMethotrexateRecurrenceChinaAntineoplastic Combined Chemotherapy Protocols

Stichwörter der Autor:innen

CNS prophylactic treatmentgenetic mutation characteristicshigh-dose methotrexateprimary breast diffuse large B-cell lymphomaradiotherapy

Substanzen

RituximabMyeloid Differentiation Factor 88Methotrexate

Autor:innen und Institutionen

  • Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
  • Department of Medical Oncology, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China.
  • Division of Medical Oncology, Cancer Center and State Key Laboratory of Biotherapy, Sichuan University, West China Hospital, Chengdu, China.
  • Institute of Cancer, Xinqiao Hospital, Army Medical University, Chongqing, China.
  • Tumour Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, China.
  • Department of Oncology, Secondary Xiangya Hospital, Central South University, Changsha, Hunan, China.

ORCID-Profile: Huawei Weng, Huangming Hong, Zegeng Chen

Förderung

  • National Natural Science Foundation of China
  • Outstanding Young Scientific and Technological Talents Fund of Sichuan Province
  • Regional Innovation Cooperation Project of Science and Technology Department of Sichuan Province

Zitieren

APA

Weng, H., Shrestha, P. R., Hong, H., Chen, Z., Yu, L., Yao, Y., Zhang, Z., Zou, L., Zhu, B., Zhou, H., Liu, X., Liu, Y., Guo, H., Huang, H., & Lin, T. (2023). Primary breast diffuse large B‐cell lymphoma in the rituximab era: A retrospective study of the Chinese Southwest Oncology Group. Cancer Medicine. https://doi.org/10.1002/cam4.6686

Vancouver

Weng H, Shrestha PR, Hong H, Chen Z, Yu L, Yao Y, et al. Primary breast diffuse large B‐cell lymphoma in the rituximab era: A retrospective study of the Chinese Southwest Oncology Group. Cancer Medicine. 2023. doi:10.1002/cam4.6686

BibTeX
@article{Weng2023,
  author = {Weng, Huawei and Shrestha, Prem Raj and Hong, Huangming and Chen, Zegeng and Yu, Le and Yao, Yuyi and Zhang, Zhihui and Zou, Liqun and Zhu, Bo and Zhou, Hui and Liu, Xianling and Liu, Yao and Guo, Hongqiang and Huang, He and Lin, Tongyu},
  title = {Primary breast diffuse large B‐cell lymphoma in the rituximab era: A retrospective study of the Chinese Southwest Oncology Group},
  journal = {Cancer Medicine},
  year = {2023},
  doi = {10.1002/cam4.6686}
}
Kostenlos starten →